Scholar Rock Holding annual working capital
2017
2018
2019
2020
2021
2022
2023
2024
2025
Scholar Rock Holding Working Capital Growth & History (SRRK)
Scholar Rock Holding's working capital was $329.7M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $329.7M | −$74.5M | −18.43% |
| 2024 | 2024-12-31 | $404.2M | $148.8M | +58.24% |
| 2023 | 2023-12-31 | $255.5M | −$36.2M | −12.41% |
| 2022 | 2022-12-31 | $291.6M | $90.6M | +45.08% |
| 2021 | 2021-12-31 | $201.0M | −$100.8M | −33.40% |
| 2020 | 2020-12-31 | $301.8M | $149.5M | +98.12% |
| 2019 | 2019-12-31 | $152.4M | $5.5M | +3.77% |
| 2018 | 2018-12-31 | $146.8M | $92.6M | +171.00% |
| 2017 | 2017-12-31 | $54.2M | — | — |
Scholar Rock Holding quarterly working capital
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $434.9M | $166.3M | +61.87% |
| Q1 2026 | 2026-03-31 | $455.6M | $108.0M | +31.05% |
| Q4 2025 | 2025-12-31 | $329.7M | −$74.5M | −18.43% |
| Q3 2025 | 2025-09-30 | $328.7M | $215.2M | +189.50% |
| Q2 2025 | 2025-06-30 | $268.7M | $102.5M | +61.72% |
| Q1 2025 | 2025-03-31 | $347.7M | $138.2M | +66.01% |
| Q4 2024 | 2024-12-31 | $404.2M | $148.8M | +58.24% |
| Q3 2024 | 2024-09-30 | $113.6M | −$88.2M | −43.71% |
| Q2 2024 | 2024-06-30 | $166.2M | −$69.4M | −29.46% |
| Q1 2024 | 2024-03-31 | $209.4M | −$51.5M | −19.74% |
| Q4 2023 | 2023-12-31 | $255.5M | −$36.2M | −12.41% |
| Q3 2023 | 2023-09-30 | $201.7M | −$122.1M | −37.71% |
| Q2 2023 | 2023-06-30 | $235.5M | −$113.4M | −32.51% |
| Q1 2023 | 2023-03-31 | $260.9M | $65.7M | +33.67% |
| Q4 2022 | 2022-12-31 | $291.6M | $90.6M | +45.08% |
| Q3 2022 | 2022-09-30 | $323.9M | $130.3M | +67.33% |
| Q2 2022 | 2022-06-30 | $349.0M | $125.6M | +56.25% |
| Q1 2022 | 2022-03-31 | $195.2M | −$53.3M | −21.46% |
| Q4 2021 | 2021-12-31 | $201.0M | −$100.8M | −33.40% |
| Q3 2021 | 2021-09-30 | $193.6M | $107.0M | +123.73% |
| Q2 2021 | 2021-06-30 | $223.3M | $110.7M | +98.32% |
| Q1 2021 | 2021-03-31 | $248.5M | $111.5M | +81.32% |
| Q4 2020 | 2020-12-31 | $301.8M | $149.5M | +98.12% |
| Q3 2020 | 2020-09-30 | $86.5M | −$60.2M | −41.03% |
| Q2 2020 | 2020-06-30 | $112.6M | −$43.7M | −27.96% |
| Q1 2020 | 2020-03-31 | $137.1M | $9.1M | +7.13% |
| Q4 2019 | 2019-12-31 | $152.4M | $5.5M | +3.77% |
| Q3 2019 | 2019-09-30 | $146.7M | $46.3M | +46.09% |
| Q2 2019 | 2019-06-30 | $156.3M | $46.1M | +41.82% |
| Q1 2019 | 2019-03-31 | $128.0M | — | — |
| Q4 2018 | 2018-12-31 | $146.8M | $92.6M | +171.00% |
| Q3 2018 | 2018-09-30 | $100.4M | — | — |
| Q2 2018 | 2018-06-30 | $110.2M | — | — |
| Q4 2017 | 2017-12-31 | $54.2M | — | — |
Scholar Rock Holding working capital trends
Over the last five fiscal years, Scholar Rock Holding's working capital increased from $301.8M to $329.7M, a change of $27.9M. The latest reported quarter, Q2 2026, shows $434.9M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...